HCA Healthcare, Inc.
421.83USD
+19.8100 (+4.93%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $6.7▼ | $7.28 | 2 | 11 |
| Next quarter | $8.01▼ | $8.36 | 8 | 7 |
| Current year | $29.49▼ | $30.14 | 7 | 10 |
| Next year | $32.07▼ | $33.11 | 6 | 11 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $7.5 | $7.59 | +0.09 (+1.2%) |
| 2026-03-31 | $7.13 | $7.15 | +0.02 (+0.3%) |
| 2025-12-31 | $7.48 | $8.01 | +0.53 (+7.1%) |
| 2025-09-30 | $5.73 | $6.96 | +1.23 (+21.6%) |
424 ratings from 43 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| RBC Capital | Reiterated | Outperform | $435 | Sep 8, 2026 |
| JP Morgan | Maintained | Neutral | $490 $425 | Aug 20, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $369 $381 | Aug 3, 2026 |
| Goldman Sachs | Maintained | Buy | $558 $485 | Jul 28, 2026 |
| Mizuho | Maintained | Outperform | $525 $475 | Jul 28, 2026 |
| UBS | Maintained | Buy | $635 $579 | Jul 27, 2026 |
| Morgan Stanley | Maintained | Underweight | $425 $380 | Jul 27, 2026 |
| RBC Capital | Reiterated | Outperform | $435 | Jul 27, 2026 |
| Truist Securities | Maintained | Buy | $535 $495 | Jul 27, 2026 |
| Oppenheimer | Maintained | Outperform | $520 $485 | Jul 27, 2026 |
| Keybanc | Maintained | Overweight | $475 $435 | Jul 27, 2026 |
| Baird | Maintained | Neutral | $396 $393 | Jul 27, 2026 |
| Barclays | Maintained | Equal-Weight | $402 $387 | Jul 27, 2026 |
| Barclays | Maintained | Equal-Weight | $427 $402 | Jul 16, 2026 |
| RBC Capital | Maintained | Outperform | $534 $435 | Jul 15, 2026 |
| Keybanc | Maintained | Overweight | $510 $475 | Jul 14, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $436 $428 | Jul 13, 2026 |
| Barclays | Downgraded from Overweight | Equal-Weight | $496 $427 | Jul 8, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $588 $525 | Jul 7, 2026 |
| TD Cowen | Maintained | Buy | $500 $431 | Jun 22, 2026 |
| Bernstein | Maintained | Market Perform | $503 $413 | Jun 4, 2026 |
| TD Cowen | Maintained | Buy | $561 $500 | Apr 27, 2026 |
| Barclays | Maintained | Overweight | $551 $496 | Apr 27, 2026 |
| RBC Capital | Maintained | Outperform | $593 $534 | Apr 27, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $481 $436 | Apr 27, 2026 |
68 filings from 21 insiders · 0 buy / 0 sell over 6m
Officers and directors of HCA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MARKS MIKE AChief Financial Officer | Gift | 3.3k | — | — | May 7, 2026 |
| SMITH ANDREA BDirector | Grant | 509 | — | — | Apr 28, 2026 |
| MICHELSON MICHAEL WDirector | Grant | 925 | — | — | Apr 28, 2026 |
| CHIDSEY JOHN WDirector | Grant | 809 | — | — | Apr 28, 2026 |
| DEPARLE NANCY-ANN M. J.D.Director | Grant | 509 | — | — | Apr 28, 2026 |
| RILEY WAYNE JOSEPHDirector | Grant | 509 | — | — | Apr 28, 2026 |
| FRIST THOMAS F IIIDirector and Beneficial Owner of more than 10% of a Class of Security | Grant | 1.0k | — | — | Apr 28, 2026 |
| JOHNSTON HUGH F.Director | Grant | 809 | — | — | Apr 28, 2026 |
| FRIST WILLIAM R.Director and Beneficial Owner of more than 10% of a Class of Security | Grant | 809 | — | — | Apr 28, 2026 |
| MCALEVEY MICHAEL R.Officer | Sell | 1.7k | $533.37 | $904k | Feb 18, 2026 |
| MCALEVEY MICHAEL R.Officer | Exercise | 5.0k | $236.61 | $1.18M | Feb 13, 2026 |
| WYATT CHRISTOPHER FOfficer | Sell | 4.0k | $505.00 | $2.02M | Feb 11, 2026 |
| BERRES JENNIFEROfficer | Sell | 8.0k | $503.00 | $4.13M | Feb 11, 2026 |
| BERRES JENNIFEROfficer | Grant | 7.1k | — | — | Feb 10, 2026 |
| MCALEVEY MICHAEL R.Officer | Grant | 8.4k | — | — | Feb 10, 2026 |
| MARKS MIKE AChief Financial Officer | Grant | 5.0k | — | — | Feb 10, 2026 |
| ROSSITTO ERICAOfficer | Grant | 1.7k | — | — | Feb 10, 2026 |
| CUFFE MICHAEL SOfficer | Grant | 9.6k | — | — | Feb 10, 2026 |
| WYATT CHRISTOPHER FOfficer | Grant | 3.4k | — | — | Feb 10, 2026 |
| HAZEN SAMUEL NChief Executive Officer | Grant | 54.9k | — | — | Feb 10, 2026 |
No analyst notes on HCA yet.
Analyst Ratings
21 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 13 | 10 | 1 | 0 | Buy2.44 |
| 1 mo ago | 1 | 13 | 10 | 1 | 0 | Buy2.44 |
| 2 mo ago | 1 | 13 | 10 | 1 | 0 | Buy2.44 |
| 3 mo ago | 2 | 13 | 9 | 1 | 0 | Buy2.36 |